News
Interim report January – September 2021
(Oslo, 9 November 2021) Genetic Analysis AS (“GA” or “the Company”) hereby publishes the interim report for the period January…
Genetic Analysis awarded important US patent covering a companion diagnostic method for optimising IBS interventions
OSLO, NORWAY – 28 October 2021: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces the award of…
Genetic Analysis enters a Service Agreement with Eurofins ADME BIOANALYSES – The first CRO to offer the GA-map® Microbiome test
OSLO, NORWAY – 19 October 2021: Molecular diagnostics specialist, Genetic Analysis AS (GA) today announced a Service Agreement with Eurofins…
Genetic Analysis receives important patent allowance in China
OSLO, NORWAY – 14 October 2021: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces that the Company…
Microbiome Dx Genetic Analysis raises USD 6.8 M in IPO
Microbiome Dx Genetic Analysis raises USD 6.8 M in IPO Closes up 50 % on first two days of trading…
Genetic Analysis AS (GEAN): First day of trading in Genetic Analysis shares and warrants on Spotlight Stock Market
OSLO, NORWAY – 1 October 2021: First day of trading in Genetic Analysis AS (“GA” or “the Company”) shares and…
Genetic Analysis AS (GEAN): Disclosure of Large Shareholding
OSLO, NORWAY – 24 September 2021: Reference is made to the press release on 15 September 2021 from Genetic Analysis…
Genetic Analysis AS (GEAN): Registration of share capital increase
OSLO, NORWAY – 24 September 2021: Reference is made to the press release on 20 September 2021 from Genetic Analysis…
Genetic Analysis AS (GEAN): Minutes from the Extraordinary General Meeting
OSLO, NORWAY – 20 September 2021: On 20 September 2021, an extraordinary general meeting in Genetic Analysis AS (“GA” or…
Genetic Analysis AS (GEAN): Mandatory notification of trade
OSLO, NORWAY – 15 September 2021: Genetic Analysis AS (“GA” or “the Company”) announce that members of the Board and…
Genetic Analysis AS (GEAN) : IPO prior to listing was significantly oversubscribed
OSLO, NORWAY – 15 September 2021: On 13 September 2021, the subscription period in Genetic Analysis AS (“GA” or “the…
Genetic Analysis AS (GEAN): Notice of Extraordinary General Meeting
OSLO, NORWAY – 13 September 2021: Notice is hereby served of an extraordinary general meeting of Genetic Analysis AS (the…
The subscription period begins in Genetic Analysis AS issue of units prior to planned listing on Spotlight Stock Market
OSLO, NORWAY – 30 August 2021: Today, the subscription period begins in Genetic Analysis (“GA” or “the Company”) issue of…
Genetic Analysis AS receives preliminary approval for listing and publishes prospectus in connection with planned IPO
OSLO, NORWAY – 24 August 2021: Genetic Analysis AS (“GA” or “the Company”) hereby announces that the Company has received…
Genetic Analysis AS releases Interim report January – June 2021
(Oslo, 20 August 2021) Genetic Analysis AS (“GA” or “the Company”) hereby publishes the interim report for the period January…
Genetic Analysis Co-develops HumGut – The world’s first complete database of reference genomes
Molecular diagnostics specialist, Genetic Analysis AS (GA) todayannounced the first publication from the comprehensive HumGut microbiome database hasappeared in the…
Eagle Biosciences Announces Agreement with Genetic Analysis AS for Distribution in North America
“North America is for sure going to accelerate the growth in the human microbiome market moving forward. We at GA…
Genetic Analysis awarded NOK 16 million to develop microbiome marker to aid treatment of Inflammatory Bowel Disease
In this project, GA will develop an easy to use, in vitro diagnostic test that profiles gutmicrobiota to predict disease…
Genetic Analysis Joins Microbiome Therapeutics Innovation Group
The Microbiome Therapeutics Innovation Group (MTIG) announced today the addition of Norwegian molecular diagnostic company Genetic Analysis AS to its…
Interview with GA’s PhD student
Pranvera Hiseni works on an industrial PhD scheme in collaboration with GA and NMBU. In addition to working on improving current detection…
Genetic Analysis AS announces that a patent was granted in the US, from family WO2016120494A
“METHOD AND PRODUCT FOR PREVENTING FALSE POSITIVES IN METHODS EMPLOYING DDNTP’S”. In March 2019, GA signed a license agreement with…
Genetic Analysis AS announces that a patent was granted in India, from family WO2012080754A2
“OLIGONUCLEOTIDE PROBE SET AND METHODS OF MICROBIOTA PROFILING”. We are very pleased to inform that our patent “Oligonucleotide probe set…
The Importance of Scale in Evaluating the Gut Microbiome
In a recent study performed by prof. Peter Malfertheiner the aim was to analyze the levels of two different types…
Launch of the GA-map COVID-19 Fecal Test.
Genetic Analysis (GA) launched in August a CE-marked IVD test to detect SARS-CoV-2 in the gut. SARS-CoV-2 has been detected…
The GA-map® Dysbiosis Test was used for microbiota determinations of the effects of high intake of cod or salmon
In a study published on the 27 October 2020 from Haukeland University Hospital the effects of high intake of cod…
Research on gastrointestinal infection on COVID-19
Research on gastrointestinal infection on COVID-19. (January 2021) The National Competence Service for Functional Gastrointestinal Diseases (NKFM) hastogether with Genetic…
Genetic Analysis AS announces that two patents were granted in Russia and EU, from family WO2016156251A1
“METHOD FOR DETERMINING GASTROINTESTINAL TRACT DYSBIOSIS”. New IP secured – Important patents enhancing the use of GA-map® granted in EU…
Successful share issue and change in the management team
Successful share issue Genetic Analysis AS announces the successful private placement of NOK 34.3 million. The issue was oversubscribed and completed in two…